• Breathtaking science

    Developing innovative therapeutics to transform

    the standard of care for respiratory diseases

  • Search for better science

    We aim to build a strong clinical R&D pipeline to

    target debilitating respiratory diseases

  • Our science

    Targeting respiratory diseases with significant unmet medical needs.

    There are millions of patients suffering globally from chronic, debilitating respiratory conditions that are not well treated by existing medicines. There is a real and pressing need for new treatments. We are focused on developing these treatments. Our efficient R&D outsourcing model gives us access to leading experts and organisations around the globe and our agility and focus on our core competencies provide the highest standards of pre-clinical and clinical development. 

    See our product pipeline

    Our strategy

    To progress projects with high commercial potential, whilst delivering both near-and long-term value to our shareholders.

    We have a clear view of the medical need and commercial potential of our novel products in global, multi-billion dollar markets. Making the right decisions now, with partners and investors, will help us identify the quickest and most effective route to market allowing us to potentially transform the lives of patients suffering from these debilating diseases, with the returns enabling us to continue this mission into the future. 

    Find out more about us

Verona Pharma

Verona Pharma plc is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as COPD and cystic fibrosis. The Company is listed on the NASDAQ Global Market in the United States under the VRNA ticker and on the London Stock Exchange in the United Kingdom under the VRP.L ticker. Read more here about Verona Pharma's science and innovative theraputics.

Latest press releases

30 November 2017

PDMR Dealing
LONDON, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage bi…

7 November 2017

Verona Pharma Reports Patient Enrollment Progressing Ahead of Schedule in Ongoing Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment
LONDON, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that it has enrolled more than 200 patients in its ongoing Phase 2b study to evaluate RPL554 for the maintenance treatment of chronic obstructive pulmonary disease (…

Financing Deal of the Year

Verona Pharma receives Financing Deal of the Year at the 2017 Scrip Awards for its successful fundraising to support the continued growth of its clinical development programmes

29 November 2017

 

Current share price

111.00p

0.50 (0.45%)

LON: VRP
 

11.51USD

-0.09 (-0.82%)

NASDAQ: VRNA
 

Contact us

Verona Pharma plc
3 More London Riverside
London SE1 2RE
United Kingdom

E: info@veronapharma.com
T: +44 (0)203 283 4200

 

 

Registered address
One Central Square
Cardiff CF10 1FS
United Kingdom

US Investor relations contact
ICR, Inc.
E: ICR_Verona@icrinc.com
T: +1 646-277-1282

UK Investor relations contact
FTI Consulting
E: veronapharma@fticonsulting.com
T: +44 (0)20 3727 1000

Nominated adviser and broker
Stifel Nicolaus Europe Limited
150 Cheapside
London EC2V 6ET
United Kingdom

T: +44 (0)207 710 7600

Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us